Literature DB >> 22674985

Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding.

Adjoa Smalls-Mantey1, Nicole Doria-Rose, Rachel Klein, Andy Patamawenu, Stephen A Migueles, Sung-Youl Ko, Claire W Hallahan, Hing Wong, Bai Liu, Lijing You, Johannes Scheid, John C Kappes, Christina Ochsenbauer, Gary J Nabel, John R Mascola, Mark Connors.   

Abstract

Antibody (Ab)-dependent cellular cytotoxicity (ADCC) is thought to potentially play a role in vaccine-induced protection from HIV-1. The characteristics of such antibodies remain incompletely understood. Furthermore, correlates between ADCC and HIV-1 immune status are not clearly defined. We screened the sera of 20 HIV-1-positive (HIV-1(+)) patients for ADCC. Normal human peripheral blood mononuclear cells were used to derive HIV-infected CD4(+) T cell targets and autologous, freshly isolated, natural killer (NK) cells in a novel assay that measures granzyme B (GrB) and HIV-1-infected CD4(+) T cell elimination (ICE) by flow cytometry. We observed that complex sera mediated greater levels of ADCC than anti-HIV-1 envelope glycoprotein (Env)-specific monoclonal antibodies and serum-mediated ADCC correlated with the amount of IgG and IgG1 bound to HIV-1-infected CD4(+) T cells. No correlation between ADCC and viral load, CD4(+) T cell count, or neutralization of HIV-1(SF162) or other primary viral isolates was detected. Sera pooled from clade B HIV-1(+) individuals exhibited breadth in killing targets infected with HIV-1 from clades A/E, B, and C. Taken together, these data suggest that the total amount of IgG bound to an HIV-1-infected cell is an important determinant of ADCC and that polyvalent antigen-specific Abs are required for a robust ADCC response. In addition, Abs elicited by a vaccine formulated with immunogens from a single clade may generate a protective ADCC response in vivo against a variety of HIV-1 species. Increased understanding of the parameters that dictate ADCC against HIV-1-infected cells will inform efforts to stimulate ADCC activity and improve its potency in vaccinees.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674985      PMCID: PMC3421757          DOI: 10.1128/JVI.00287-12

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing.

Authors:  Xueling Wu; Tongqing Zhou; Jiang Zhu; Baoshan Zhang; Ivelin Georgiev; Charlene Wang; Xuejun Chen; Nancy S Longo; Mark Louder; Krisha McKee; Sijy O'Dell; Stephen Perfetto; Stephen D Schmidt; Wei Shi; Lan Wu; Yongping Yang; Zhi-Yong Yang; Zhongjia Yang; Zhenhai Zhang; Mattia Bonsignori; John A Crump; Saidi H Kapiga; Noel E Sam; Barton F Haynes; Melissa Simek; Dennis R Burton; Wayne C Koff; Nicole A Doria-Rose; Mark Connors; James C Mullikin; Gary J Nabel; Mario Roederer; Lawrence Shapiro; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2011-08-11       Impact factor: 47.728

2.  Antigenic variation in gp120s from molecular clones of HIV-1 LAI.

Authors:  J P Moore; H Yoshiyama; D D Ho; J E Robinson; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  1993-12       Impact factor: 2.205

3.  Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection.

Authors:  R Ahmad; S T Sindhu; E Toma; R Morisset; J Vincelette; J Menezes; A Ahmad
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

4.  Sera from HTLV-III/LAV antibody-positive individuals mediate antibody-dependent cellular cytotoxicity against HTLV-III/LAV-infected T cells.

Authors:  A H Rook; H C Lane; T Folks; S McCoy; H Alter; A S Fauci
Journal:  J Immunol       Date:  1987-02-15       Impact factor: 5.422

5.  Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.

Authors:  R A Koup; J L Sullivan; P H Levine; F Brewster; A Mahr; G Mazzara; S McKenzie; D Panicali
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

6.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

8.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort.

Authors:  A Dalgleish; A Sinclair; M Steel; D Beatson; C Ludlam; J Habeshaw
Journal:  Clin Exp Immunol       Date:  1990-07       Impact factor: 4.330

View more
  63 in total

Review 1.  Beyond Viral Neutralization.

Authors:  George K Lewis; Marzena Pazgier; David T Evans; Guido Ferrari; Stylianos Bournazos; Matthew S Parsons; Nicole F Bernard; Andrés Finzi
Journal:  AIDS Res Hum Retroviruses       Date:  2017-02-16       Impact factor: 2.205

Review 2.  Unravelling the mechanisms of durable control of HIV-1.

Authors:  Bruce D Walker; Xu G Yu
Journal:  Nat Rev Immunol       Date:  2013-07       Impact factor: 53.106

3.  Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells.

Authors:  Shayarana L Gooneratne; Jonathan Richard; Wen Shi Lee; Andrés Finzi; Stephen J Kent; Matthew S Parsons
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

4.  Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Authors:  Wen Shi Lee; Anne B Kristensen; Thomas A Rasmussen; Martin Tolstrup; Lars Østergaard; Ole S Søgaard; Bruce D Wines; P Mark Hogarth; Arnold Reynaldi; Miles P Davenport; Sean Emery; Janaki Amin; David A Cooper; Virginia L Kan; Julie Fox; Henning Gruell; Matthew S Parsons; Stephen J Kent
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

Review 5.  Antibody-dependent cellular cytotoxicity in HIV infection.

Authors:  Donald N Forthal; Andrés Finzi
Journal:  AIDS       Date:  2018-11-13       Impact factor: 4.177

6.  Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.

Authors:  Sung-Youl Ko; Amarendra Pegu; Rebecca S Rudicell; Zhi-yong Yang; M Gordon Joyce; Xuejun Chen; Keyun Wang; Saran Bao; Thomas D Kraemer; Timo Rath; Ming Zeng; Stephen D Schmidt; John-Paul Todd; Scott R Penzak; Kevin O Saunders; Martha C Nason; Ashley T Haase; Srinivas S Rao; Richard S Blumberg; John R Mascola; Gary J Nabel
Journal:  Nature       Date:  2014-08-13       Impact factor: 49.962

7.  Roles of fragment crystallizable-mediated effector functions in broadly neutralizing antibody activity against HIV.

Authors:  Ali Danesh; Yanqin Ren; R Brad Jones
Journal:  Curr Opin HIV AIDS       Date:  2020-09       Impact factor: 4.283

8.  HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.

Authors:  Justin Pollara; Mattia Bonsignori; M Anthony Moody; Pinghuang Liu; S Munir Alam; Kwan-Ki Hwang; Thaddeus C Gurley; Daniel M Kozink; Lawrence C Armand; Dawn J Marshall; John F Whitesides; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Merlin L Robb; Robert J O'Connell; Jerome H Kim; Nelson L Michael; David C Montefiori; Georgia D Tomaras; Hua-Xin Liao; Barton F Haynes; Guido Ferrari
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

9.  Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques.

Authors:  C Moog; N Dereuddre-Bosquet; J-L Teillaud; M E Biedma; V Holl; G Van Ham; L Heyndrickx; A Van Dorsselaer; D Katinger; B Vcelar; S Zolla-Pazner; I Mangeot; C Kelly; R J Shattock; R Le Grand
Journal:  Mucosal Immunol       Date:  2013-04-17       Impact factor: 7.313

10.  Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.

Authors:  Diego A Vargas-Inchaustegui; Marjorie Robert-Guroff
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.